Core 1: Specimen and Data Core
核心 1:样本和数据核心
基本信息
- 批准号:10629194
- 负责人:
- 金额:$ 33.34万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-04-04 至 2025-03-31
- 项目状态:未结题
- 来源:
- 关键词:AntibodiesAntibody titer measurementB-LymphocytesBioinformaticsBiologicalBiological MarkersBiological Specimen BanksBiologyBiometryBiopsyBloodBlood specimenCaringCellsClinicalClinical DataClinical ResearchClinical TreatmentCollaborationsCollectionCommunitiesComplexConsentDataDatabasesDiseaseEarly DiagnosisEnrollmentEnsureGuidelinesImmuneImmunobiologyImmunologic MarkersImmunooncologyImmunophenotypingImmunotherapyIndividualInstitutionInterest GroupInternationalLaboratoriesLaboratory ResearchLinkLongitudinal StudiesMedicalMerkel CellsMerkel cell carcinomaNational Comprehensive Cancer NetworkOncoproteinsOutcomePD-1 blockadePatient-Focused OutcomesPatientsPolyomavirusProcessProductivityPublicationsQualifyingRecommendationRecurrenceRecurrent diseaseResearchResource SharingResourcesRoleSamplingScientistSerology testSpecimenTestingTimeTissuesTranslational ResearchTumor AntibodiesTumor BurdenTumor Tissueburden of illnesschemotherapycohortdata repositorydemographicsexome sequencingfallsimmune checkpoint blockadeimprovedinsightmultidimensional dataparticipant enrollmentprogrammed cell death protein 1programsrelational databaserepositoryresearch clinical testingresearch studyresponsetranscriptome sequencingtranscriptomicstumor
项目摘要
Summary: Specimen and Data Core
The proposed Specimen & Data Core will serve several central roles within this highly integrated Program
Project: 1) it will consent and enroll all Merkel cell carcinoma (MCC) patients into our longitudinal research
study; 2) it will acquire, process, and store all patient blood and tumor tissue and distribute them to the relevant
Projects and the Immunophenotyping Core; and 3) it will obtain patient clinical data over time, and store
research-derived patient results, annotating the samples with corresponding disease status. The proposed
Core will expand both our existing MCC Specimen Repository that has over 20,000 individual specimens from
1,400 patients (as of May 2018) and our Relational Database that annotates those samples and patient
demographics using approximately 200 data fields including clinical treatments, disease status, and response
data, as well as research laboratory results.
A proposed, essential new role for the Specimen and Data Core will be to acquire tumor samples (including
biopsies obtained for research purposes, rather than only those that were clinically required) from patients
before and after PD-1 checkpoint blockade therapy. Obtaining such tissues is complex and laborious but also
essential for understanding the basis of response and non-response to these important new immune therapies.
An expansion of our Relational Database will involve the addition of over 30 fields to capture new
immunotherapy-related results and experimental data that will be useful for the Projects as well as for the
Immunophenotyping Core and Biostatistics & Bioinformatics Core. The Specimen and Data Core will also track
MCPyV oncoprotein antibody titers to assist in a) detecting early disease recurrence, b) understanding how to
use this recently developed test in patients undergoing PD-1 checkpoint blockade therapy, and c) assisting
Project 3 in understanding the biological basis of why these antibodies rapidly fall when tumor is removed.
Lastly, the Specimen & Data Core will leverage these precious resources by sharing samples and data with the
broader MCC and scientific communities through collaborative studies that have proven extremely productive
in the past, with 43 publications (through May 2018) that have made use of repository specimens and data. 39
of those publications have also involved collaborations with groups outside of Seattle.
摘要:标本和数据核心
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
PAUL NGHIEM其他文献
PAUL NGHIEM的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('PAUL NGHIEM', 18)}}的其他基金
Immunobiology and Immune Therapy for Merkel Cell Carcinoma
默克尔细胞癌的免疫生物学和免疫治疗
- 批准号:
9906874 - 财政年份:2019
- 资助金额:
$ 33.34万 - 项目类别:
Project 2: Characterizing and overcoming failure to respond to PD-1 blockade therapy
项目 2:描述和克服对 PD-1 阻断疗法无反应的问题
- 批准号:
10380818 - 财政年份:2019
- 资助金额:
$ 33.34万 - 项目类别:
Project 2: Characterizing and overcoming failure to respond to PD-1 blockade therapy
项目 2:描述和克服对 PD-1 阻断疗法无反应的问题
- 批准号:
10629191 - 财政年份:2019
- 资助金额:
$ 33.34万 - 项目类别:
Immunobiology and Immune Therapyfor Merkel Cell Carcinoma
默克尔细胞癌的免疫生物学和免疫治疗
- 批准号:
10629189 - 财政年份:2019
- 资助金额:
$ 33.34万 - 项目类别:
Immunobiology and Immune Therapyfor Merkel Cell Carcinoma
默克尔细胞癌的免疫生物学和免疫治疗
- 批准号:
10380816 - 财政年份:2019
- 资助金额:
$ 33.34万 - 项目类别:
Mechanisms of UV-induced DNA damage responses and carcinogenesis in skin
紫外线诱导的皮肤 DNA 损伤反应和致癌机制
- 批准号:
9038985 - 财政年份:2015
- 资助金额:
$ 33.34万 - 项目类别:
Pathogenetic and prognostic studies for improved therapy of Merkel cell carcinoma
默克尔细胞癌改进治疗的发病机制和预后研究
- 批准号:
8699412 - 财政年份:2014
- 资助金额:
$ 33.34万 - 项目类别:
相似海外基金
Establishment of antibody titer measurement against Vibrio vulnificus
创伤弧菌抗体滴度测定方法的建立
- 批准号:
19592091 - 财政年份:2007
- 资助金额:
$ 33.34万 - 项目类别:
Grant-in-Aid for Scientific Research (C)